CN118251218A - 使用prmt5抑制剂治疗癌症的组合疗法 - Google Patents

使用prmt5抑制剂治疗癌症的组合疗法 Download PDF

Info

Publication number
CN118251218A
CN118251218A CN202280067397.9A CN202280067397A CN118251218A CN 118251218 A CN118251218 A CN 118251218A CN 202280067397 A CN202280067397 A CN 202280067397A CN 118251218 A CN118251218 A CN 118251218A
Authority
CN
China
Prior art keywords
alkyl
cancer
hydrogen
haloalkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280067397.9A
Other languages
English (en)
Chinese (zh)
Inventor
P·奥尔森
L·D·恩斯特罗姆
J·G·克里斯滕森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CN118251218A publication Critical patent/CN118251218A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280067397.9A 2021-10-06 2022-10-06 使用prmt5抑制剂治疗癌症的组合疗法 Pending CN118251218A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252995P 2021-10-06 2021-10-06
US63/252,995 2021-10-06
PCT/US2022/045895 WO2023059795A1 (en) 2021-10-06 2022-10-06 Combination therapies using prmt5 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN118251218A true CN118251218A (zh) 2024-06-25

Family

ID=84053165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280067397.9A Pending CN118251218A (zh) 2021-10-06 2022-10-06 使用prmt5抑制剂治疗癌症的组合疗法

Country Status (10)

Country Link
US (1) US20240398795A1 (https=)
EP (1) EP4412607A1 (https=)
JP (1) JP2024538719A (https=)
KR (1) KR20240095421A (https=)
CN (1) CN118251218A (https=)
AU (1) AU2022360837A1 (https=)
CA (1) CA3233157A1 (https=)
IL (1) IL311663A (https=)
MX (1) MX2024004171A (https=)
WO (1) WO2023059795A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202626A1 (zh) * 2022-04-22 2023-10-26 北京望实智慧科技有限公司 稠和哒嗪酮化合物作为prmt5抑制剂
CN119301101A (zh) * 2022-07-29 2025-01-10 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0922332D0 (en) * 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
EP3177288A4 (en) * 2014-08-04 2018-04-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3191592A1 (en) * 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
TW202122387A (zh) 2019-09-12 2021-06-16 美商米瑞替療法公司 Mta協同性之prmt5抑制劑
AU2020410418A1 (en) * 2019-12-18 2022-06-09 Pfizer Inc. Once daily cancer treatment regimen with a PRMT5 inhibitor
WO2021138578A1 (en) * 2019-12-31 2021-07-08 The Trustees Of Indiana University Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5

Also Published As

Publication number Publication date
IL311663A (en) 2024-05-01
JP2024538719A (ja) 2024-10-23
CA3233157A1 (en) 2023-04-13
MX2024004171A (es) 2024-04-23
EP4412607A1 (en) 2024-08-14
WO2023059795A1 (en) 2023-04-13
AU2022360837A1 (en) 2024-04-18
KR20240095421A (ko) 2024-06-25
US20240398795A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
US12128048B2 (en) Combination therapies using PRMT5 inhibitors for the treatment of cancer
US20250073241A1 (en) Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer
ES3004338T3 (en) Combination therapies
EP2793892A1 (en) Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of pi3k/mtor with bendamustine and/or rituximab
CN118251218A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
CN119836290A (zh) 使用prmt5抑制剂和bcl-2家族抑制剂治疗癌症的组合疗法
EP2701690A1 (en) Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
CN117769420A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
CN117769421A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
EA051338B1 (ru) Комбинированная терапия с использованием ингибиторов prmt5 для лечения рака
WO2025217015A1 (en) Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer
WO2025217007A1 (en) Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025217008A1 (en) Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer
EA049653B1 (ru) Комбинированная терапия с применением ингибиторов prmt5 для лечения рака

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination